




National Jewish Health and Subsidiary

**Consolidated Financial Statements
(With Independent Auditor's Report Thereon)**

June 30, 2024 and 2023



National Jewish Health and Subsidiary
Contents
June 30, 2024 and 2023

Contents

Independent Auditor’s Report..... 1

Consolidated Financial Statements

 Statements of Financial Position..... 4

 Statements of Activities 6

 Statements of Cash Flows 8

 Notes to Financial Statements 10

Independent Auditor's Report

Board of Directors
National Jewish Health
Denver, Colorado

Opinion

We have audited the consolidated financial statements of National Jewish Health and Subsidiary (National Jewish Health) which comprise the consolidated statements of financial position as of June 30, 2024 and 2023, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of National Jewish Health as of June 30, 2024 and 2023, and the changes in their net assets and their cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of National Jewish Health and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about National Jewish Health's ability to continue as a going concern for one year after the date that these consolidated financial statements are issued.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of National Jewish Health's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about National Jewish Health's ability to continue as a going concern for a reasonable period of time.

Board of Directors
National Jewish Health

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Forvis Mazars, LLP

**Denver, Colorado
October 25, 2024**

National Jewish Health and Subsidiary
Consolidated Statements of Financial Position (In thousands)
June 30, 2024 and 2023

	<u>2024</u>	<u>2023</u>
ASSETS		
Current Assets		
Cash and cash equivalents	\$ 29,707	\$ 14,519
Accounts receivable		
Patient care	25,662	28,357
Pledges and bequests, net	18,245	24,632
Contributions receivable - program services	13,977	9,122
Receivable from joint ventures	-	4,281
Other receivables	12,169	10,937
Assets held by trustees - current portion	3,059	3,007
Prepaid and other	5,503	6,979
	<u>108,322</u>	<u>101,834</u>
Assets Whose Use is Limited		
Internally-designated assets	36,602	38,057
Assets held under split interest	5,908	5,956
Assets held by trustees - net of current portion	853	783
	<u>43,363</u>	<u>44,796</u>
Other Assets		
Long-term investments	78,533	75,027
Pledges, net of current portion and allowance	9,260	13,141
Beneficial interest under perpetual and other trust agreements	13,961	13,182
Contributions receivable under unitrust agreements	2,803	2,685
Right-of-use assets - operating leases	4,083	5,809
Right-of-use assets - finance leases	361	192
Right-of-use assets - building finance lease	67,097	68,898
Other	3,952	4,338
	<u>180,050</u>	<u>183,272</u>
Property and Equipment		
Land, building and equipment, net	82,293	87,229
	<u>82,293</u>	<u>87,229</u>
Total assets	<u>\$ 414,028</u>	<u>\$ 417,131</u>

National Jewish Health and Subsidiary
Consolidated Statements of Financial Position (In thousands)
June 30, 2024 and 2023

(Continued)

	<u>2024</u>	<u>2023</u>
LIABILITIES AND NET ASSETS		
Current Liabilities		
Accounts payable and accrued expenses	\$ 18,782	\$ 23,678
Refundable advances, current portion	8,963	5,346
Accrued salaries, wages, and employee benefits	13,412	11,641
Unearned revenue	2,271	2,474
Estimated settlements with third-party payors	2,985	3,684
Split-interest agreements, current portion	1,335	1,298
Long-term debt, current portion	2,925	2,815
Operating lease liabilities, current portion	1,653	1,840
Finance lease liabilities, current portion	189	80
Building finance lease liabilities, current portion	4,293	4,292
	<u>56,808</u>	<u>57,148</u>
Total current liabilities		
Split-interest agreements, net of current portion	7,648	7,242
Long-term debt, net of current portion	9,405	12,384
Operating lease liabilities, net of current portion	2,703	4,267
Finance lease liabilities, net of current portion	214	146
Building finance lease, net of current portion	65,062	66,443
Other	4,137	5,170
	<u>145,977</u>	<u>152,800</u>
Total liabilities		
Net Assets		
Without donor restrictions	111,668	103,053
With donor restrictions	156,383	161,278
	<u>268,051</u>	<u>264,331</u>
Total net assets		
Total liabilities and net assets	<u>\$ 414,028</u>	<u>\$ 417,131</u>

National Jewish Health and Subsidiary
Consolidated Statements of Activities (In thousands)
Years Ended June 30, 2024 and 2023

	<u>2024</u>	<u>2023</u>
Changes in Net Assets Without Donor Restrictions		
Revenue, gains, and other support without donor restrictions		
Patient service revenue	\$ 163,470	\$ 150,430
Grant research awards	59,292	55,612
Health initiatives revenue	16,218	15,469
Revenue from joint ventures	-	414
Other operating revenue	121,549	94,469
Gifts, special events - net and bequests	16,194	13,151
Split-interest contributions	237	366
Investment income, net	5,685	4,792
	<u>382,645</u>	<u>334,703</u>
Net Assets Released from Restriction	24,328	28,497
Expenses		
Academic services	108,124	107,118
Clinical services	202,499	177,709
Other programs	13,777	13,926
Fund development	8,714	7,607
Administration and support services	64,548	63,254
	<u>397,662</u>	<u>369,614</u>
Other Expense		
Change in split-interest agreements	<u>(696)</u>	<u>(337)</u>
	<u>(696)</u>	<u>(337)</u>
Increase (decrease) in net assets without donor restrictions	<u>8,615</u>	<u>(6,751)</u>

National Jewish Health and Subsidiary
Consolidated Statements of Activities (In thousands)
Years Ended June 30, 2024 and 2023

(Continued)

	<u>2024</u>	<u>2023</u>
Changes in Net Assets With Donor Restrictions		
Program services	58	20
Gifts, special events, and bequests	15,232	14,080
Change in value of split-interest agreements	(390)	600
Investment income, net	9,798	4,723
Contributions - restricted in perpetuity	335	112
Loss on pledge receivable	<u>(5,600)</u>	<u>-</u>
Total revenue with donor restrictions	19,433	19,535
Total net assets released from restrictions	<u>(24,328)</u>	<u>(28,497)</u>
Decrease in net assets with donor restrictions	<u>(4,895)</u>	<u>(8,962)</u>
Increase (Decrease) in Net Assets	3,720	(15,713)
Net Assets, Beginning of Year	<u>264,331</u>	<u>280,044</u>
Net Assets, End of Year	<u>\$ 268,051</u>	<u>\$ 264,331</u>

National Jewish Health and Subsidiary
Consolidated Statements of Cash Flows (In thousands)
Years Ended June 30, 2024 and 2023

	<u>2024</u>	<u>2023</u>
Cash Flows from Operating Activities		
Increase (decrease) in net assets	\$ 3,720	\$ (15,713)
Items not requiring (providing) cash		
Depreciation	9,881	8,759
Amortization - finance lease	1,910	1,887
Unrealized gain	(7,357)	(5,821)
Increase in net assets with		
donor restrictions in perpetuity	(335)	(112)
Loss on pledge receivable	5,600	-
Bond premium, discount, and issuance cost amortization	(54)	(54)
Noncash operating lease expense	1,917	191
Changes in		
Patient care accounts receivable	2,695	(126)
Pledges and bequests receivable	4,668	(263)
Other current assets	4,525	(5,331)
Contributions receivable - program services	(4,855)	(1,765)
Contributions receivable - other	(118)	(639)
Beneficial interest under perpetual trust	(779)	(579)
Other assets	(747)	(683)
Estimated third-party payor settlements	(699)	(596)
Accounts payable and accrued expenses, workers		
compensation, accrued salaries, wages, and		
employees benefits and unearned grants	(3,987)	3,061
Refundable advances	3,617	(2,846)
Cash paid for operating lease liability	(1,940)	-
	<u>17,662</u>	<u>(20,630)</u>
Net cash provided by (used in) operating activities		

National Jewish Health and Subsidiary
Consolidated Statements of Cash Flows (In thousands)
Years Ended June 30, 2024 and 2023

(Continued)

	<u>2024</u>	<u>2023</u>
Cash Flows from Investing Activities		
Purchases of property and equipment	(4,945)	(18,798)
Purchases of internally designated assets	(3,591)	(25,300)
Proceeds from sale of internally designated assets	6,924	24,765
(Purchases) proceeds from sale of assets held by trustees	(109)	8
Purchases of investments and assets reserved for gift annuities	(14,477)	(11,020)
Proceeds from sale of investments and assets reserved for gift annuities	17,243	30,516
	<u>1,045</u>	<u>171</u>
Net cash provided by investing activities	1,045	171
Cash Flows from Financing Activities		
Repayment of long-term debt and finance lease liabilities	(4,296)	(5,347)
Increase (decrease) in split-interest liability	442	(294)
Proceeds from net assets with donor restrictions in perpetuity	335	112
	<u>(3,519)</u>	<u>(5,529)</u>
Net cash used in financing activities	(3,519)	(5,529)
Net increase (decrease) in cash and cash equivalents	15,188	(25,988)
Cash and Cash Equivalents, Beginning of Year	<u>14,519</u>	<u>40,507</u>
Cash and Cash Equivalents, End of Year	<u>\$ 29,707</u>	<u>\$ 14,519</u>
Supplemental Schedule of Noncash Activities		
Cash paid for interest	\$ 3,588	\$ 3,704
ROU assets obtained in exchange for new finance lease liabilities	\$ 280	\$ -
ROU assets obtained in exchange for new operating lease liabilities	\$ 89	\$ 3,038

Note 1. Corporate Organization

Organization

National Jewish Health and Subsidiary (National Jewish Health), a Colorado nonprofit corporation, is the leading respiratory hospital in the nation. Founded in 1899 as a nonsectarian charity hospital for tuberculosis patients, National Jewish Health today is the only facility in the world dedicated substantially to groundbreaking medical research and treatment of patients with respiratory, cardiac, immune and related disorders.

National Jewish Health is a nonprofit corporation as described in Section 501(c)(3) of the Internal Revenue Code (IRC) and is exempt from federal income taxes on related income pursuant to Section 501(a) of the IRC and a similar provision of state law.

In 2002, the National Jewish Illiquid Assets Holding Company, LLC, a wholly owned subsidiary of National Jewish Health, was incorporated. The purpose of this subsidiary is to hold donated property until sold. All related intercompany transactions and balances have been eliminated in consolidation.

Joint Ventures

Effective December 2013, National Jewish Health formed a limited liability corporation in a joint venture with the Icahn School of Medicine doing business as the Mount Sinai – National Jewish Respiratory Institute to oversee the creation and operations of a joint respiratory institute at various sites in the Mount Sinai integrated health care system in New York City, New York.

Effective August 2014, National Jewish Health entered into a joint operating agreement with Intermountain Healthcare (formerly Sisters of Charity of Leavenworth (SCL) Health)/St. Joseph Hospital for the joint management and operation of National Jewish Health's in-state patient care and St. Joseph Hospital. The new entity is overseen by a Board of Directors with representation from both entities.

Effective April 2017, National Jewish Health formed a limited liability corporation in a joint venture with Thomas Jefferson University doing business as the Jane and Leonard Korman Jefferson Health | National Jewish Health Respiratory Institute to oversee the development and operations of a joint respiratory institute at various sites in the Jefferson Health System in Philadelphia, Pennsylvania.

Note 2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts or revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Contributions, Promises to Give and Bequests

National Jewish Health receives funding from a number of sources such as: individuals, foundations, government programs, corporations, and pharmaceutical companies. Some contributions are restricted to specific purposes. These are provided for various programs including, but not limited to research, smoking cessation services, and educational programs.

Contributions received from donors and other funding agencies are recorded as net assets without donor restrictions, unless otherwise stipulated by the donor or agency. If the contribution is restricted, revenue is recorded to net assets with donor restrictions at the time of receipt or commitment is received, whichever is earlier. When the donor restriction expires, the contribution is reclassified to net assets without donor restrictions through net assets released from restriction in the consolidated statements of activities. All expenses directly related to donor restrictions are included in the appropriate expense category on the net assets without donor restrictions section of the consolidated statements of activities, creating a reduction in net assets without donor restrictions.

Unconditional promises to give expected to be collected within one year are recorded at fair value, while if collection is expected in future years they are recorded at their estimated fair value, which represents the present value of their estimated future cash flows. Amortization of the related present value discounts is included in contribution revenue.

Conditional promises to give are not included as revenue, gains, and other support without donor restrictions until the conditions placed on the gift by the donor or agency are substantially met. When the contribution is both conditional and restricted to a purpose, and both of these are met simultaneously, National Jewish Health has elected to record contribution revenue directly to net assets without donor restrictions according to the simultaneous release accounting election provided in FASB Accounting Standards Codification 958-605-45-4B.

Bequest income is recognized when all of the following criteria are met: (1) National Jewish Health has received notification of the donor's death; (2) National Jewish Health has a copy of the valid will or trust document evidencing the bequest; and (3) the value of the gift can be reasonably estimated. Accrued bequest income is shown as net assets with donor restrictions until received.

Contributions restricted to purchase property, plant, and equipment are reported as net assets with donor restrictions, then released to without donor restrictions when purchased and placed in service, unless the donor stipulates how long the assets must be used. In that case, the restriction is released as stipulated and the asset is depreciated over the asset's useful life.

Split-Interest Agreements

National Jewish Health receives certain planned gift agreements in which National Jewish Health has an interest in the assets and receives benefits that are shared with another beneficiary designated by the donor. These contributions are termed split-interest agreements. National Jewish Health benefits from the following types of split-interest agreements: irrevocable charitable remainder trusts, charitable lead trusts, charitable gift annuities, pooled income funds, and perpetual trusts. Assets are invested and payments made to the appropriate beneficiary in accordance with the agreements. The fair value of the future payments is recorded as a liability.

Assets held under the split-interest agreements were \$5,908 and \$5,956 as of June 30, 2024 and 2023, respectively, and were recorded in the appropriate investment category. When applicable, the amounts to be received in future periods were discounted using a risk-adjusted rate of 5.3% in addition to the expected term of the split-interest agreements.

The amount of the contribution is recorded as the difference between the asset and the liability as revenue without donor restrictions unless otherwise restricted by the donor. Subsequent changes in the fair value are recorded as change in split-interest agreements on the consolidated statements of activities.

Included in long term investments, are assets held to meet the mandated annuity reserves as required by the governing state the agreement was written in.

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Grant Research Awards

Total grant research awards consist of grants from the federal government, charitable foundations, and private corporations. These grants are classified as exchange transactions if the grantor is receiving the direct benefit of the research and contributions. Most grants are contributions where the public receives the direct benefit. All grants have a restricted purpose and most are conditional. This is determined from the award document.

Generally, both the condition and restricted purposes are met simultaneously and National Jewish Health has elected the expediency of recording these grant awards to revenues, gains and other support without donor restrictions when the conditions and restrictions have been met. Unconditional restricted contributions are recorded to revenue, gains, and other support with donor restrictions at the time the grant is awarded, and released to revenue, gains, and other support without donor restrictions when the restricted purpose has been met.

Exchange transactions are recorded directly to revenue, gains, and other support without donor restrictions as performance obligations are met over time. Both the contributions and the exchange transactions are recorded as grant research awards in the consolidated statements of activities. The composition of total grant revenue for the years ended June 30, 2024 and 2023 is:

	2024			2023		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Contributions	\$ 54,852	\$ -	\$ 54,852	\$ 51,817	\$ -	\$ 51,817
Exchange transactions	4,440	-	4,440	3,795	-	3,795
	<u>\$ 59,292</u>	<u>\$ -</u>	<u>\$ 59,292</u>	<u>\$ 55,612</u>	<u>\$ -</u>	<u>\$ 55,612</u>

At June 30, 2024 and 2023, National Jewish Health had \$51,685 and \$49,061, respectively, of conditional contributions remaining consisting of federal grants and non-federal grants whose conditions and restrictions relate to National Jewish Health expending allowable costs. These agreements had award end dates ranging from one month to seven years.

Additionally, at June 30, 2024 and 2023, National Jewish Health had \$25,279 and \$20,883, respectively, of conditional contributions remaining consisting of state smoking cessation contracts whose conditions and restrictions relate to National Jewish Health performing services related to the contract. These contracts had award end dates ranging from three months to three years.

Cash and Cash Equivalents

Cash and cash equivalents include investments in highly liquid debt instruments with original maturities of three months or less. Cash and cash equivalents included in long-term investments, endowment accounts, and assets limited as to use restricted internally by the board or externally are not considered to be cash and cash equivalents.

Debt Issuance Costs

Bond issuance costs and bond discounts related to the issuance of bonds are deferred and amortized over the life of the respective bond issue using the straight-line method. Additionally, capital lease issuance costs related to the issuance of capital leases are deferred and amortized over the life of the capital lease using the straight-line method.

Investments and Net Investment Return

Investment income, net includes interest and other investment income, dividend, realized and unrealized gains and losses on investments, less investment expenses. Investment income from endowment investments is reflected in net assets with donor restrictions, then is released from restriction when the Board appropriates the funds for expenditures. Other investment income is reflected in net assets without donor restrictions.

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Property and Equipment

Property and equipment is stated at cost if purchased, or if donated, is recorded at fair value at the date of donation. If donors stipulate how long the assets must be used, the contributions are recorded as net assets with donor restrictions, otherwise, they are recorded as net assets without donor restrictions. Non-depreciable assets (land) at June 30, 2024 and 2023 is \$13,157 and \$13,171, respectively. Depreciation of buildings and equipment is calculated using the straight-line method over the estimated useful lives of the assets in accordance with American Hospital Association guidelines. Depreciation expense for 2024 and 2023, respectively, is \$9,881 and \$8,759, while accumulated depreciation is \$152,217 and \$143,848. The estimated useful lives for buildings is 20 – 40 years and for equipment and software is 3 – 15 years. Assets under capital lease obligations and leasehold improvements are amortized over the shorter of the lease term or their respective estimated useful lives.

Long-Lived Asset Impairment

National Jewish Health evaluates the recoverability of the carrying value of long-lived assets whenever events or circumstances indicate the carrying amount may not be recoverable. If a long-lived asset is tested for recoverability and the undiscounted estimate of future cash flows expected to result from the use and eventual disposition of the asset is less than the carrying amount of the asset, the asset cost is adjusted to fair value and an impairment loss is recognized as the amount by which the carrying amount of a long-lived asset exceeds its fair value. There was no asset impairment loss in fiscal years ended June 30, 2024 and 2023.

Net Assets

Net assets, revenues, gains and losses are classified based on the existence or absence of donor or grantor restrictions.

Net assets without donor restrictions are available for use in general operations and not subject to donor or certain grantor restrictions. The governing board has designated, from net assets without donor or certain grantor restrictions, net assets for operating reserves and an endowment.

Net assets with donor restrictions are subject to donor or certain grantor restrictions. Some restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other restrictions are perpetual in nature, where the donor or grantor stipulates that resources be maintained in perpetuity.

Patient Service Revenue

Patient service revenue is recognized as National Jewish Health satisfies performance obligations under its contracts with patients. Patient service revenue is reported at the estimated transaction price or amount that reflects the consideration National Jewish Health expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors, and others for services rendered, taking into consideration both explicit price concessions (such as contractual agreements) and implicit price concessions (such as uncollectible self-pay portions). National Jewish Health pursues collection of self-pay portions, but anticipates a small amount of loss based on historical results. Due to insurance plans, government programs, charitable financial policies (state and National Jewish Health), and uncollectibles, amounts received are generally less than established billing rates.

Other Operating Revenue

Other operating revenue is primarily composed of contract pharmacy revenue totaling \$107,973 and \$80,434 for the years ended 2024 and 2023, respectively. The revenue is earned at a point in time as the performance obligation is met. Remaining other operating revenue also includes physician contracted services, radiology services, and other miscellaneous revenue.

Subsequent Events

Subsequent events have been evaluated through October 25, 2024, which is the date the consolidated financial statements were issued.

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Presentation of Financial Statements

Management has elected to present the financial statements under the not-for-profit model rather than the healthcare model since National Jewish Health's non-patient revenues, gains and other support are historically in excess of patient service revenue. The difference in presentation would have no effect on the change in net assets.

Note 3. Patient Service Revenue

Patient service revenue generally relates to contracts with patients in which the performance obligations are to provide health care services to patients over a period of time. Revenue is estimated for patients who have not been discharged as of the reporting period based on actual charges incurred to date in relation to total expected charges. National Jewish Health believes this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. The contractual relationship with patients also typically involves a third-party payer (Medicare, Medicaid, managed care plans, and commercial insurance companies), and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payers. The payment arrangements with third-party payers for the services provided to the related patients typically specify payment or reimbursement to National Jewish Health at other-than-standard charges.

Since all of its performance obligations relate to contracts with a duration of less than one year, National Jewish Health has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a), so is not required to disclose the aggregate amount of the transaction price allocated to performance obligations which are unsatisfied or partially unsatisfied at the end of the reporting period. National Jewish Health has also elected the practical expedient allowed under FASB ASC 606-10-32-18 so patient accounts are not adjusted for a financing component since National Jewish Health's expectation is accounts will be paid within one year. Generally, National Jewish Health bills within several days for services provided and the majority of receivables are paid within one year of service. National Jewish Health does enter into contracts where payments extend beyond one year. In these limited cases, the financing component is not deemed to be significant to the contract.

National Jewish Health determines the transaction price based on standard charges for goods and services provided, reduced by explicit price concessions which consist of contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with its policy, and implicit price concessions provided to uninsured patients. National Jewish Health determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. National Jewish Health determines its estimate of implicit price concessions based on its historical collection experience with private pay and uninsured patients. For the fiscal years ended June 30, 2024 and 2023, implicit price concessions were \$1,830 and \$1,926, respectively.

National Jewish Health has determined the nature, amount, timing and uncertainty of revenue and cash flows are affected by payer class. The composition of patient service revenue by primary payor for the fiscal years ended 2024 and 2023 is as follows:

	<u>2024</u>	<u>2023</u>
Medicare	\$ 57,372	\$ 52,557
Medicaid	25,805	22,765
Managed Care, Commercial and Other	78,981	73,645
Self-Pay	<u>1,312</u>	<u>1,463</u>
Total patient service revenue	<u>\$ 163,470</u>	<u>\$ 150,430</u>

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the National Jewish Health's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon National Jewish Health. In addition, the contracts National Jewish Health has with commercial payors also provide for retroactive audit and review of claims.

National Jewish Health provides services in Colorado to patients from throughout the United States and internationally. As of June 30, 2024 and 2023, National Jewish Health's patient care receivable for services rendered was \$25,662 and \$28,357, respectively.

Settlements with third-party payers for retroactive adjustments due to cost report or other audits and reviews are variable consideration and are included in the determination of the estimated transaction price for providing patient care. This includes an assessment to ensure it is probable a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known based on newly available information or as years are settled or no longer subject to such audits and reviews. Adjustments arising from a change in the transaction price were not significant in 2024 nor 2023.

Consistent with National Jewish Health's mission, care is provided to patients regardless of their ability to pay. Financial assistance is made available to patients based upon their ability to pay, and determinations in individual cases are made during National Jewish Health's preadmission process. Because National Jewish Health does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue. Expansion of eligibility coverage under Medicaid by the Affordable Care Act has decreased charity care substantially.

National Jewish Health's direct and indirect costs for services furnished under its charity care policy totaled \$448 and \$306 in 2024 and 2023, respectively. National Jewish Health also participates in the Medicare and Medicaid programs. Under these programs, National Jewish Health provides care to patients at payment rates determined by governmental agencies, regardless of actual cost. Governmental rates are frequently below cost.

Note 4. Natural and Functional Expense Analysis

The tables below present expenses by both their nature and their function for the fiscal years ended June 30, 2024 and 2023.

	June 30, 2024					
	Program Activities			Supporting Activities		
	Academic Services	Clinical Services	Other Services	Fund Development	Administration and Support Services	FY24 Total Expenses
Salaries and fringe benefits expense	\$ 83,630	\$ 53,232	\$ 6,841	\$ 5,126	\$ 39,618	\$ 188,447
Professional fees	4,565	7,628	2,039	964	6,235	21,431
Medical supplies and drugs expense	4,259	120,223	2,955	1	761	128,199
Occupancy expense	1,134	4,005	59	472	9,914	15,584
Office expense	601	424	383	773	2,090	4,271
Depreciation and interest	4,547	9,999	381	269	1,784	16,980
Collaborative agreements	6,292	-	-	-	-	6,292
Other expense	3,096	6,988	1,119	1,109	4,146	16,458
Total expenses	<u>\$ 108,124</u>	<u>\$ 202,499</u>	<u>\$ 13,777</u>	<u>\$ 8,714</u>	<u>\$ 64,548</u>	<u>\$ 397,662</u>

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

	June 30, 2023					
	Program Activities			Supporting Activities		
	Academic Services	Clinical Services	Other Services	Fund Development	Administration and Support Services	FY23 Total Expenses
Salaries and fringe benefits expense	\$ 82,759	\$ 50,772	\$ 6,364	\$ 4,452	\$ 38,462	\$ 182,809
Professional fees	5,375	7,162	3,054	608	6,317	22,516
Medical supplies and drugs expense	4,637	99,216	2,816	-	825	107,494
Occupancy expense	1,098	4,355	104	627	8,698	14,882
Office expense	674	445	334	825	2,649	4,927
Depreciation and interest	3,483	9,248	372	231	1,687	15,021
Collaborative agreements	6,111	-	-	-	-	6,111
Other expense	2,981	6,511	882	864	4,616	15,854
Total expenses	<u>\$ 107,118</u>	<u>\$ 177,709</u>	<u>\$ 13,926</u>	<u>\$ 7,607</u>	<u>\$ 63,254</u>	<u>\$ 369,614</u>

The consolidated financial statements report certain categories of expenses attributable to more than one program or support function. Therefore, these expenses require allocation on a reasonable basis that is applied consistently. The expenses include depreciation and interest allocated based on the percentage of total expenses.

Note 5. Liquidity and Availability of Funds

The following reflects National Jewish Health's liquid financial assets available to meet cash needs for general expenditures for the period of one year after the consolidated statements of financial position dates of June 30, 2024 and 2023.

	2024	2023
Cash and cash equivalents	\$ 29,707	\$ 14,519
Patient care	25,662	28,357
Contributions receivable, without donor restrictions	13,977	9,122
Receivable from joint ventures	-	4,281
Pledges without donor restrictions and bequests, net	261	1,683
Other	12,169	10,937
Total liquid financial assets	<u>\$ 81,776</u>	<u>\$ 68,899</u>

National Jewish Health maintains a line of credit in the amount of \$15,000, which it could draw upon in the event of liquidity needs. This line of credit is unused as of June 30, 2024. National Jewish Health also has board-designated and donor-restricted assets limited to use which the institution does not intend to spend outside of approved expenditures. Of these, the internally designated assets of \$35,116 at June 30, 2024, may be drawn upon, if necessary, to meet unexpected liquidity needs.

National Jewish Health invests cash in excess of daily requirements in various short-term instruments as allowed by the investment policy.

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Note 6. Promises to Give

The following are unconditional promises to give recognized as receivables as of June 30, 2024 and 2023:

	<u>2024</u>	<u>2023</u>
Pledges and bequests, before discount and allowances	\$ 39,998	\$ 44,310
Less unamortized discount – pledges	(1,888)	(1,726)
Less allowance for uncollectibles – pledges and bequests	<u>(10,605)</u>	<u>(4,811)</u>
Net unconditional promises to give	<u>\$ 27,505</u>	<u>\$ 37,773</u>
Amounts due in		
Less than one year	\$ 25,028	\$ 25,855
One to five years	8,865	12,325
More than five years	<u>6,105</u>	<u>6,130</u>
Total	<u>\$ 39,998</u>	<u>\$ 44,310</u>

Discount rates are established when the promise to give is made. Discount rates ranged from 0.37% to 4.64% for fiscal years ended June 30, 2024 and 2023, respectively.

Note 7. Contributions Receivable

Contributions receivable are due within one year and for the fiscal years ended June 30, 2024 and 2023, consists of the following:

	Without Donor Restrictions	
	<u>2024</u>	<u>2023</u>
Grants	\$ 10,214	\$ 5,239
Health initiatives	3,705	3,782
Professional education	<u>58</u>	<u>101</u>
Total	<u>\$ 13,977</u>	<u>\$ 9,122</u>

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Note 8. Internally-Designated Assets

The governing body has designated certain assets for strategic and other future purposes. On June 30, 2024 and 2023, the composition of internally designated assets stated at fair value, as determined by the most recent market quotations or an estimate based on significant other observable inputs are stated below:

	<u>2024</u>	<u>2023</u>
Cash and cash equivalents	\$ 1,226	\$ 896
Common stocks and equity funds	8,017	9,214
International securities and equities funds	5,199	5,105
Fixed income securities funds	8,234	8,821
U.S. government and agency obligations funds	9,009	9,953
Alternative investments	4,917	4,068
	<u>\$ 36,602</u>	<u>\$ 38,057</u>

Note 9. Long-Term Investments

The composition of long-term investments, stated at fair value, as determined by the most recent market quotations or an estimate based on significant other observable inputs at June 30, 2024 and 2023 is as follows:

	<u>2024</u>	<u>2023</u>
Cash and cash equivalents	\$ 1,201	\$ 330
Convertible securities and equities funds	20,838	26,487
International securities and equities funds	9,218	9,702
Fixed income securities funds	6,303	5,016
U.S. government and agency obligations funds	8,217	6,168
Alternative investments	32,756	27,324
	<u>\$ 78,533</u>	<u>\$ 75,027</u>

Investments as of June 30, 2024 and 2023 include gift annuity investments of \$9,873 and \$11,251, respectively, and the fair value of the gift annuity obligations under those agreements was \$6,938 and \$6,963, respectively. Reserves for gift annuities are held in separate investment accounts with required minimums as required by appropriate state requirements.

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Note 10. Composition of Investment Returns

The following summarizes investment returns and classification in the consolidated statements of activities:

	2024	
	Without Donor Restriction	With Donor Restriction
Interest income, net	\$ 2,193	\$ 1,111
Gains		
Realized gains	1,003	3,819
Unrealized gain	<u>2,489</u>	<u>4,868</u>
Total gains	<u>3,492</u>	<u>8,687</u>
Total return on investments in stock and bond portfolios	<u>\$ 5,685</u>	<u>\$ 9,798</u>
	2023	
	Without Donor Restriction	With Donor Restriction
Interest income, net	\$ 2,771	\$ 1,024
Gains (losses)		
Realized gains (losses)	(346)	246
Unrealized gains	<u>2,367</u>	<u>3,453</u>
Total gains	<u>2,021</u>	<u>3,699</u>
Total return on investments in stock and bond portfolios	<u>\$ 4,792</u>	<u>\$ 4,723</u>

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Note 11. Long-Term Debt

Long-term debt at June 30, 2024 and 2023 is summarized as follows:

	<u>2024</u>	<u>2023</u>
Revenue Bonds, Series 2012 (a)	\$ 5,360	\$ 7,675
Revenue Bonds, Series 2005 (b)	6,900	7,400
Unamortized Bond Premium		
Revenue Bonds, Series 2012	<u>240</u>	<u>333</u>
	12,500	15,408
Less: unamortized debt issuance costs	(170)	(209)
Less: current portion	<u>(2,925)</u>	<u>(2,815)</u>
	<u>\$ 9,405</u>	<u>\$ 12,384</u>

Series 2012 Revenue Bonds

The Colorado Health Facilities Authority issued \$26,790 aggregate principal amount of its Refunding Revenue Bonds Series 2012 (the 2012 Bonds) dated March 1, 2012. The proceeds were used to refund the Series 1998 and Series 1998B Bonds. The 2012 Bonds are subject to a mandatory sinking fund redemption beginning January 1, 2026. Final principal payments on the bonds are due in January 2027. Redemption amounts are as follows at June 30, 2024:

2025	\$ 2,425
2026	2,555
2027	<u>380</u>
	<u>\$ 5,360</u>

The 2012 Bonds bear interest at fixed rates varying from 3.00% to 5.00% and are secured by the rights to all future revenue derived from National Jewish Health's property, excluding revenue derived from donor-restricted property if such revenue is unavailable for debt service. The 2012 Bonds are subject to covenants which impose certain operating and financial restrictions on National Jewish Health. Management believes National Jewish Health is in compliance with all covenants for the years ended June 30, 2024 and 2023. Unamortized debt issuance costs for the 2012 Bonds were \$77 and \$107 at June 30, 2024 and 2023, respectively.

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Series 2005 Revenue Bonds

In January 2005, the Colorado Health Facilities Authority issued \$13,500 aggregate principal amount of its Series 2005 Revenue Bonds (the 2005 Bonds) dated January 20, 2005. Proceeds from the 2005 Bonds were used to finance the construction of a clinical and research building, as well as several renovation projects and equipment. Unamortized debt issuance costs for the 2005 Bonds were \$93 and \$102 at June 30, 2024 and 2023, respectively.

The 2005 Bonds require annual payments of varying amounts. These payments began on January 1, 2007. Final principal payments on the bonds are due in January 2035. Redemption amounts are as follows at June 30, 2024:

2025	\$	500
2026		500
2027		500
2028		600
2029		600
Thereafter		<u>4,200</u>
	\$	<u>6,900</u>

The 2005 Bonds bear a variable rate of interest based on the rate at which the bonds could be remarketed at their face value and are secured by the rights to all future revenue derived from National Jewish Health's property, excluding revenue derived from donor-restricted property if such revenue is unavailable for debt service. The interest rate at June 30, 2024 was 3.98%. The 2005 Bonds are backed by an irrevocable transferable letter of credit, which is automatically extended without amendment for an additional period of 12 months. The letter of credit expires March 1, 2026, and is automatically extended by one year, each year, beginning March 1, unless otherwise terminated before the updated expiration date. Unless certain events occur, such as the expiration date of the letter of credit, advances made on the letter of credit are not due for 366 days from the date of the advance. At June 30, 2024 and 2023, no borrowings were outstanding. The 2005 Bonds are subject to covenants, which impose certain operating and financial restrictions on National Jewish Health. Management believes National Jewish Health is in compliance with all covenants for the years ended June 30, 2024 and 2023.

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Held by Trustee

Assets held by trustees represent funds designated by the bond indenture to pay principal and interest on the 2012 and 2005 Bonds. These funds, which are comprised of cash and cash equivalents and fixed income funds, relate to the following as of June 30, 2024 and 2023:

	2024		
	Cash and Cash Equivalents	Fixed Income	Total
2012 Bonds			
Bond Reserve Fund	\$ 2,520	\$ 241	\$ 2,761
Bond Interest/Principal Fund	286	-	286
	<u>\$ 2,806</u>	<u>\$ 241</u>	<u>\$ 3,047</u>
2005 Bonds			
Bond Reserve Fund	\$ 795	\$ -	\$ 795
Bond Interest/Principal Fund	70	-	70
	<u>\$ 865</u>	<u>\$ -</u>	<u>\$ 865</u>
	2023		
	Cash and Cash Equivalents	Fixed Income	Total
2012 Bonds			
Bond Reserve Fund	\$ 2,276	\$ 473	\$ 2,749
Bond Interest/Principal Fund	216	-	216
	<u>\$ 2,492</u>	<u>\$ 473</u>	<u>\$ 2,965</u>
2005 Bonds			
Bond Reserve Fund	\$ 793	\$ -	\$ 793
Bond Interest/Principal Fund	32	-	32
	<u>\$ 825</u>	<u>\$ -</u>	<u>\$ 825</u>

Note 12. Line of Credit

National Jewish Health has a \$15,000 unsecured revolving bank line of credit expiring on March 1, 2026. At June 30, 2024 and 2023, there was \$0 borrowed against this line. Interest accrues at a floating per annum rate of interest at the borrower's option of (a) 30 day SOFR rate plus 1.85% (b) 90 day SOFR rate plus 1.85% or (c) Prime Rate less 1%. Either selection shall not be less than 4.25%. National Jewish Health's borrowing interest rate was 7.19% and 6.95% on June 30, 2024 and 2023, respectively.

Note 13. Leases

Accounting Policies

National Jewish Health determines if an arrangement is a lease or contains a lease at inception. Each arrangement with monthly payments in excess of \$5,000 and total lease liability in excess of \$75,000 result in the recognition of right-of-use (ROU) assets and lease liabilities on the statements of financial position. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease, measured on a discounted basis. National Jewish Health determines lease classification as operating or finance at the lease commencement date and reports each on the statements of financial position on separate lines.

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

National Jewish Health elected not to combine lease and nonlease components, such as common area and other maintenance costs, property taxes, service and warranty agreements, in calculating the ROU assets and lease liabilities for its office buildings and equipment.

At lease inception, the lease liability is measured at the present value of the lease payments over the lease term. The ROU asset equals the lease liability adjusted for any initial direct costs, prepaid or deferred rent, and lease incentives. For finance leases, National Jewish Health uses the implicit rate when readily determinable. As most of the finance leases do not provide an implicit rate, National Jewish Health uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of lease payments. For finance leases, National Jewish Health determines the present value of lease payments using the incremental or stated borrowing rate. For operating leases, National Jewish Health has made a policy election to use a risk-free rate (the rate of a zero-coupon U.S. Treasury instrument) for the initial and subsequent measurement. The risk-free rate is determined using a period comparable with the lease term.

The lease term may include options to extend or to terminate the lease that National Jewish Health is reasonably certain to exercise. Lease expense is generally recognized on a straight-line basis over the lease term.

National Jewish Health has elected not to record leases with an initial term of 12 months or less on the statements of financial position. Lease expense on such leases is recognized on a straight-line basis over the lease term.

Nature of Leases

National Jewish Health has entered into the following lease arrangements:

Finance Leases

These leases consist of the Building Finance Lease described below as well as other office and medical equipment leases. Termination of the leases generally are prohibited unless there is a violation under the lease agreements. Amortization of finance lease right-of-use asset was \$1,910 and \$1,887 for the years ended June 30, 2024 and 2023, respectively. Interest paid on finance lease liabilities was \$2,888 and \$2,952 for the years ended June 30, 2024 and 2023, respectively. The weighted average remaining lease term and discount rate for the years ended June 30, 2024 and 2023 was 37.3 years and 4.23%; and 38.39 years and 4.22%, respectively.

Building Finance Lease

On October 16, 2019, Colorado Health Facilities Authority Revenue Bonds (NJH-SJH Center for Outpatient Health project) Series 2019 in the aggregate principal of \$72,050 were issued on behalf of the NJH-SJH Center for Outpatient Health LLC (the Borrower), to fund construction of the Center for Outpatient Health building on land owned by National Jewish Health. The bonds were issued at a premium. The cash received in excess of \$72,050 approximated the amount of interest paid on the bonds prior to National Jewish Health occupying the newly constructed building in fiscal year 2023. This land is on the National Jewish Health main campus, and leased to the Borrower of the bonds. Concurrently, National Jewish Health entered into an installment sale contract with the Borrower for use and eventual purchase of the Center for Outpatient Health building. Obligations to make payments under the installment sale contract is a non-recourse obligation of National Jewish Health's limited to National Jewish Health's interest in the building and land.

The payment obligation under the installment sale contract is identical in timing and amount to the obligations of the Borrower under the bonds, which bear interest at fixed rates varying from 3.00% to 5.00% and terminates January 1, 2050. Payments under the installment sales contract began January 1, 2023. The obligation under the installment sale contract is guaranteed by Intermountain Health.

As of June 30, 2024 and 2023, \$72,050 of the bond funds have been expended for construction costs. Since the facility is included in National Jewish Health's joint operating agreement (JOA) with Intermountain Health | St. Joseph Hospital, 75% of the depreciation and interest for the facility will be recovered from Intermountain Health | St. Joseph Hospital through the JOA. The Center for Outpatient Health opened in fall 2021.

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Operating Leases

National Jewish Health leases office space, clinic space, and a variety of equipment that expire in various years through 2029. These leases generally contain renewal options for periods ranging from 1 to 5 years and require National Jewish Health to pay all executory costs (property taxes, maintenance and insurance). Lease payments have an escalating fee schedule, which range from a 0% to 3% percent increase each year. Termination of the leases is generally prohibited unless there is a violation under the lease agreement. Operating lease cost was approximately \$1,917 and \$2,338 for the years ended June 30, 2024 and 2023, respectively. Cash paid for amounts included in the measurement of operating lease liabilities was approximately \$1,940 and \$2,212, respectively. The weighted average remaining lease term and discount rate for the years ended June 30, 2024 and 2023 was 3.23 years and 2.35%; and 3.84 years and 2.03%, respectively.

Short-Term Leases

National Jewish Health leases certain equipment with an expected lease terms are less than 12 months. Total lease expense included in operating expenses for the years ended June 30, 2024 and 2023, was \$12 and \$20, respectively.

All Leases

National Jewish Health has no material related-party leases. National Jewish Health's lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Future minimum lease payments and reconciliation to the consolidated statements of financial position at June 30, 2024, are as follows:

	Finance Leases	Operating Leases
2025	\$ 4,482	\$ 1,653
2026	4,437	1,273
2027	4,382	915
2028	4,295	602
2029	4,291	115
Thereafter	90,124	-
Total future undiscounted lease payments	112,011	4,558
Less future interest expense	42,253	202
Lease liabilities	<u>\$ 69,758</u>	<u>\$ 4,356</u>

Note 14. Commitments and Contingencies

Professional Liability

Professional liability reserve estimates represent the estimated ultimate cost of all reported and unreported losses incurred through the respective consolidated statements of financial position. The reserves for unpaid losses and loss expenses are estimated using individual case-basis valuations and actuarial analyses. Those estimates are subject to the effects of trends in loss severity and frequency. The estimates are continually reviewed and adjustments are recorded as experience develops or new information becomes known. The time period required to resolve these claims can vary depending upon whether the claim is settled or litigated. The estimation of the timing of payments beyond a year can vary significantly. Although considerable variability is inherent in professional liability reserve estimates, we believe the reserves for losses and loss expenses are adequate based on information currently known. It is reasonably possible this estimate could change materially in the near term.

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Other

National Jewish Health has certain pending litigation and claims incurred in the ordinary course of business; however, management believes, based on the advice of legal counsel, the probable resolution of such contingencies will not materially affect the financial position or operations of National Jewish Health.

National Jewish Health maintains professional and general liability coverage through a claims-made policy with COPIC Insurance. The policy's liability is \$1,000 per medical incident and \$3,000 in the aggregate, with deductibles of \$100 per medical incident/occurrence and \$300 in the aggregate. In addition, umbrella coverage is provided to National Jewish Health through a claims-made policy with COPIC Insurance. The liability limit under the umbrella policy is \$20,000 combined medical incident and in aggregate.

Risks and Uncertainties

National Jewish Health invests in securities which are exposed to various risks such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible changes in the values of investment securities will occur in the near term and those changes could materially affect the investment amounts reported in the consolidated statements of financial position.

Non-Cancelable Purchase Obligations

During 2024, National Jewish Health entered into a non-cancelable purchase commitment to purchase products and services, such as medical equipment. As of June 30, 2024, the total outstanding non-cancelable purchase obligation over the next ten years was \$7,369.

Note 15. Net Assets

Net Assets With Donor Restrictions

Net assets with donor restrictions at June 30, 2024 and 2023, are restricted for the following purpose or periods.

Net assets reserved for future unrestricted uses represent contributions not yet received by National Jewish Health. Endowed assets not yet appropriated for expenditure represent earnings on permanently endowed funds which have not been appropriated for expenditure by National Jewish Health in a manner consistent with the standard of prudence prescribed by State of Colorado Prudent Management of Institutional Funds Act (SPMIFA).

	<u>2024</u>	<u>2023</u>
Net assets reserved for future unrestricted uses	\$ 2	\$ 939
Subject to expenditure for specified purpose		
Research, education, patient care		
and capital construction	69,265	73,192
Endowed asset earnings not yet appropriated for expenditure	28,373	24,083
Unitrust and pooled income agreements	7,276	7,111
Beneficial interest in perpetual trust agreements	13,961	13,182
Permanent endowments	<u>37,506</u>	<u>42,771</u>
	<u>\$ 156,383</u>	<u>\$ 161,278</u>

National Jewish Health is an income beneficiary of several perpetual trusts controlled by unrelated third-party trustees. The trust document or the trustees' policies govern the investment and distribution of trust assets. Trust income distributed to National Jewish Health for the years ended June 30, 2024 and 2023 was \$617 and \$698, respectively.

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Net Assets Without Donor Restrictions

Net assets without donor restrictions at June 30, 2024 and 2023, are comprised of both designated and undesignated amounts as follows:

	<u>2024</u>	<u>2023</u>
Undesignated	\$ 76,552	\$ 66,362
Designated by the board for operating reserve	25,191	22,712
Designated by the board for endowment	<u>9,925</u>	<u>13,979</u>
Net assets without donor restrictions	<u>\$ 111,668</u>	<u>\$ 103,053</u>

Net Assets Released from Restrictions

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purposes or by occurrence of other events specified by donors.

	<u>2024</u>	<u>2023</u>
Expiration of time restrictions	\$ 7,948	\$ 228
Subject to expenditures for specified purposes		
Research, education, patient care		
and capital construction	13,384	23,840
Distributions (proceeds are not restricted by donors)		
Beneficial interests in charitable trusts held by others	313	259
Release of appropriated endowment amounts		
without purpose restrictions	2,197	3,696
Release of appropriated endowment amounts		
with purpose restrictions	<u>486</u>	<u>474</u>
	<u>\$ 24,328</u>	<u>\$ 28,497</u>

Note 16. Endowment

National Jewish Health's endowment consists of approximately 83 individual donor-restricted funds established as endowments and intended for a variety of purposes. The endowment includes both donor-restricted endowment funds and funds designated by the Board of Directors to function as endowments. As required by United States of America generally accepted accounting principles (GAAP), net assets associated with endowment funds, including board-designated endowment funds, are classified and reported based on the existence or absence of donor-imposed restrictions.

The Board of Directors has interpreted SPMIFA as requiring the preservation of the fair value of the original gift as of the gift date of the endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, National Jewish Health classifies amounts in its donor-restricted endowment funds as net assets with donor restrictions because those net assets are time restricted until the board appropriates such amounts for expenditure. Most of those net assets are also subject to the purpose restrictions which must be met before classifying those net assets to net assets without donor restrictions. The Board of Directors has also interpreted SPMIFA as permanently restricted net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure by the organization in a manner consistent with the standard of prudence prescribed by SPMIFA. National Jewish Health has interpreted SPMIFA to permit spending from underwater funds in accordance with the prudent measures required under the law. National Jewish Health considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- 1) The duration and preservation of the fund
- 2) The purpose of National Jewish Health and the donor-restricted endowment fund
- 3) General economic conditions
- 4) The possible effect of inflation and deflation
- 5) The expected total return from income and appreciation of investments
- 6) The resources of National Jewish Health
- 7) The investment policies of National Jewish Health

Investment Policy

National Jewish Health has adopted investment and spending policies for endowment assets which attempt to provide a predictable stream of funding to programs supported by the endowment while balancing fund growth. Under this policy, approved by the Board of Directors, the assets are invested in a manner intended to produce results which exceed Consumer Price Index plus 5% per year as measured over a rolling 36-month period. To satisfy this long-term rate of return objective, National Jewish Health relies on a total return strategy in which investment returns are achieved through both capital appreciation and current yield. National Jewish Health targets a diversified asset allocation that places a greater emphasis on equity-based investments to achieve its long-term return objectives with prudent risk constraints.

Spending Policy

National Jewish Health's spending policy varies by the purpose of the endowment and was established by the Board of Directors after considering all seven factors outlined by SPMIFA above. Funds with donor specific purposes have a spending policy of between 3% and 4% of the market value of the fund averaged over the past 12 fiscal quarters prior to when the distribution is made. Spending from unrestricted endowments should range from 0% to 5% of the market value of the fund averaged over 12 fiscal quarters prior to when the distribution is made.

National Jewish Health has a policy that permits spending from underwater endowment funds depending on the degree to which the fund is underwater, unless otherwise precluded by donor stipulations or laws and regulations. No expenditures from underwater endowment funds were appropriated for during the years ended June 30, 2024 and 2023.

The composition of net assets by type of endowment at June 30, 2024:

	<u>Without Donor Restriction</u>	<u>With Donor Restriction</u>	<u>Total</u>
Donor-restricted endowment funds	\$ -	\$ 68,625	\$ 68,625
Board-designated endowment funds	9,925	-	9,925
Total funds	<u>\$ 9,925</u>	<u>\$ 68,625</u>	<u>\$ 78,550</u>

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Changes in endowment net assets for fiscal year ended June 30, 2024:

	<u>Without Donor Restriction</u>	<u>With Donor Restriction</u>	<u>Total</u>
Endowment net assets, beginning of year	\$ 13,979	\$ 69,391	\$ 83,370
Contributions	-	335	335
Loss of pledge receivable	-	(5,600)	(5,600)
Endowment transfer	(5,000)	(3,791)	(8,791)
Investment income	245	740	985
Net assets released from restriction	-	(69)	(69)
Gain on sale of investments	152	2,940	3,092
Unrealized gain on investments	549	4,679	5,228
	<u>\$ 9,925</u>	<u>\$ 68,625</u>	<u>\$ 78,550</u>
Endowment net assets, end of year	<u>\$ 9,925</u>	<u>\$ 68,625</u>	<u>\$ 78,550</u>

The composition of net assets by type of endowment fund at June 30, 2023:

	<u>Without Donor Restriction</u>	<u>With Donor Restriction</u>	<u>Total</u>
Donor-restricted endowment funds	\$ -	\$ 69,391	\$ 69,391
Board-designated endowment funds	13,979	-	13,979
	<u>\$ 13,979</u>	<u>\$ 69,391</u>	<u>\$ 83,370</u>
Total funds	<u>\$ 13,979</u>	<u>\$ 69,391</u>	<u>\$ 83,370</u>

Changes in endowment net assets for fiscal year ended June 30, 2023:

	<u>Without Donor Restriction</u>	<u>With Donor Restriction</u>	<u>Total</u>
Endowment net assets, beginning of year	\$ 13,064	\$ 70,922	\$ 83,986
Contributions	-	112	112
Endowment transfer	-	(5,153)	(5,153)
Investment income	320	771	1,091
Net assets released from restriction	-	(120)	(120)
Loss on sale of investments	(167)	(376)	(543)
Unrealized gain on investments	762	3,235	3,997
	<u>\$ 13,979</u>	<u>\$ 69,391</u>	<u>\$ 83,370</u>
Endowment net assets, end of year	<u>\$ 13,979</u>	<u>\$ 69,391</u>	<u>\$ 83,370</u>

Note 17. Fair Value Disclosure

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements must maximize the use of observable inputs and minimize the use of unobservable inputs. A hierarchy of three levels of inputs may be used to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities

Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets which are not active, other inputs which are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Level 3: Unobservable inputs which are supported by little or no market activity and are significant to the fair value of the assets or liabilities

Recurring Measurements

The following tables represent the fair value measurement of assets recognized in the accompanying consolidated statements of financial position measured at fair value on a recurring basis and the level within the ASC 820 fair value hierarchy in which the fair value measurements fall at June 30, 2024 and 2023:

June 30, 2024	Fair Value	Fair Value Measurements at Reporting Date Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Internally-designated assets				
Common stocks and equity funds	\$ 8,017	\$ 8,017	\$ -	\$ -
International securities and equities	5,199	5,199	-	-
Fixed income securities	8,234	8,234	-	-
U.S. government and agency securities	9,009	9,009	-	-
Alternative investments (A)	4,917	-	-	-
Total internally-designated assets	35,376	30,459	-	-
Assets reserved for gift annuities				
Common stocks and equity funds	1,966	1,966	-	-
International securities and equities	2,021	2,021	-	-
U.S. government and agency securities	1,770	1,770	-	-
Total assets reserved for gift annuities	5,757	5,757	-	-
Long-term investments				
Convertible securities and equities	20,876	20,876	-	-
International securities and equities	9,218	9,218	-	-
Fixed income securities	6,303	6,303	-	-
U.S. government and agency securities	8,217	8,217	-	-
Alternative investments (A)	32,718	-	-	-
Total long-term investments	77,332	44,614	-	-
Other				
Beneficial interest in perpetual trust	13,961	-	-	13,961
Total other	13,961	-	-	13,961
Total assets above	132,426	\$ 80,830	\$ -	\$ 13,961
Cash and cash equivalents not included above	2,578			
Total	\$ 135,004			

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

<u>June 30, 2023</u>	<u>Fair Value</u>	<u>Fair Value Measurements at Reporting Date Using</u>		
		<u>Quoted Prices in Active Markets for Identical Assets (Level 1)</u>	<u>Significant Other Observable Inputs (Level 2)</u>	<u>Significant Unobservable Inputs (Level 3)</u>
Internally-designated assets				
Common stocks and equity funds	\$ 9,214	\$ 9,214	\$ -	\$ -
International securities and equities	5,105	5,105	-	-
Fixed income securities	8,821	8,821	-	-
U.S. government and agency securities	9,953	9,953	-	-
Alternative investments (A)	4,068	-	-	-
Total internally-designated assets	<u>37,161</u>	<u>33,093</u>	<u>-</u>	<u>-</u>
Assets reserved for gift annuities				
Common stocks and equity funds	1,065	1,065	-	-
International securities and equities	2,775	2,775	-	-
Fixed income securities	947	947	-	-
U.S. government and agency securities	1,024	1,024	-	-
Total assets reserved for gift annuities	<u>5,811</u>	<u>5,811</u>	<u>-</u>	<u>-</u>
Long-term investments				
Convertible securities and equities	26,487	26,487	-	-
International securities and equities	9,702	9,702	-	-
Fixed income securities	5,016	5,016	-	-
U.S. government and agency securities	6,168	6,168	-	-
Alternative investments (A)	27,324	-	-	-
Total long-term investments	<u>74,697</u>	<u>47,373</u>	<u>-</u>	<u>-</u>
Other				
Beneficial interest in perpetual trust	13,182	-	-	13,182
Total other	<u>13,182</u>	<u>-</u>	<u>-</u>	<u>13,182</u>
Total assets above	<u>130,851</u>	<u>\$ 86,277</u>	<u>\$ -</u>	<u>\$ 13,182</u>
Cash and cash equivalents not included above	<u>1,371</u>			
Total	<u>\$ 132,222</u>			

(A) Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The fair value amounts included above are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated statements of financial position.

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Following is a description of the valuation methodologies and inputs used for assets and liabilities measured at fair value on a recurring basis and recognized in the accompanying consolidated statements of financial position, as well as the general classification of such assets and liabilities pursuant to the valuation hierarchy. There have been no significant changes in the valuation techniques during the year ended June 30, 2024.

Investments

Where quoted market prices are available in an active market, securities are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available, then fair values are estimated by using quoted prices of securities with similar characteristics or independent asset pricing services and pricing models, the inputs of which are market-based or independently sourced market parameters, including, but not limited to, yield curves, interest rates, volatilities, prepayments, defaults, cumulative loss projections and cash flows. Such securities are classified in Level 2 of the valuation hierarchy. In certain cases, where Level 1 or Level 2 inputs are not available, securities are classified within Level 3 of the hierarchy.

Beneficial Interest in Perpetual Trust

Fair value is estimated at the present value of the trust assets using quoted market prices of securities with similar characteristics or independent asset pricing services and pricing models, the inputs of which are market-based or independently sourced market parameters. Due to the trusts being held into perpetuity, National Jewish Health will not have the ability to redeem the corpus, and therefore it is classified within Level 3 of the hierarchy.

Alternative Investments

Except as described below, the fair value of alternative investments has been estimated using the net asset value per share of the investments. Alternative investments held at June 30 consist of the following:

		June 30, 2024			
		Fair Value	Unfunded	Redemption Frequency	Redemption Notice Period
Funds of Funds	\$	37,635	\$ 10,764	Quarterly or Fund Termination	60 Days or Fund Termination
		June 30, 2023			
		Fair Value	Unfunded	Redemption Frequency	Redemption Notice Period
Funds of Funds	\$	31,392	\$ 14,647	Quarterly or Fund Termination	60 Days or Fund Termination

This category includes investments in funds of funds that pursue multiple strategies to diversify risks and reduce volatility. The funds' composite portfolio includes investments in U.S. common stocks, global real estate projects, private equity, pooled income vehicles and arbitrage investments. However, as of June 30, 2024, it is probable all investments in this category will be sold at an amount different from the net asset value of National Jewish Health's ownership interest in partners' capital. Therefore, the fair values of the investments in this category have been estimated using recent observable transaction information for similar investments. Investments with quarterly redemptions require lock-up periods of one year which has expired on the funds currently held. Of the remaining funds, they cannot be liquidated prior to the termination of the fund without the approval of the General Manager of the fund. Investment in the funds is intended to be long-term.

National Jewish Health and Subsidiary
Notes to Consolidated Financial Statements (In thousands)
June 30, 2024 and 2023

Level 3 Reconciliation

The following is a reconciliation and ending balances of recurring fair value measurements recognized in the accompanying consolidated statements of financial position using significant unobservable (Level 3) inputs:

	Beneficial Interest in Perpetual Trust
Balance, June 30, 2022	\$ 12,603
Unrealized appreciation on investments in net assets	<u>579</u>
Balance, June 30, 2023	13,182
Unrealized appreciation on investments in net assets	<u>779</u>
Balance, June 30, 2024	<u><u>\$ 13,961</u></u>

Unobservable (Level 3) Inputs

The following table presents quantitative information about unobservable inputs used in recurring Level 3 fair value measurements.

Description	Fair Value June 30, 2024	Valuation Technique	Unobservable Inputs	Range Weighted Average
Beneficial Interest in Perpetual Trusts	\$ 13,961	Fair value of trust assets	Lack of redeemability	Not Applicable

Description	Fair Value June 30, 2023	Valuation Technique	Unobservable Inputs	Range Weighted Average
Beneficial Interest in Perpetual Trusts	\$ 13,182	Fair value of trust assets	Lack of redeemability	Not Applicable

Note 18. Employee Benefit Plans

National Jewish Health maintains a defined contribution plan (the Plan) covering substantially all benefit eligible employees. Under the terms of the Plan, National Jewish Health contributes between 5% and 6% of an employee's covered wages up to the Social Security wage base and between 10% and 11% of covered wages in excess of the Social Security wage base. The Plan contains no provisions requiring National Jewish Health to match a portion of employee contributions. Expenses under the Plan for 2024 and 2023 approximated \$6,837 and \$6,717, respectively.

Note 19. Related-Party Transactions

National Jewish Health from time-to-time in the normal course of business and within the guidelines of its conflict of interest policy, has entered into transactions with companies for which certain members of the companies' management also serve on the board of National Jewish Health. Management believes prices paid by National Jewish Health have been equal to or less than the prices that would have been paid in transactions with parties not related to National Jewish Health.